STO-3 PUBLICATIONS & ABSTRACTS
Clinical evidence from STO-3
Evidence / Endocrine / STO-3
Differential Long-Term Benefit of 2-Year Adjuvant Tamoxifen Therapy for Luminal-Type Breast Cancer: Insights From a 20-Year Follow-Up Analysis of the STO Trials
Title: Differential long-term benefit of 2-year adjuvant tamoxifen therapy for luminal-type breast cancer: Insights from a 20-year follow-up analysis of the STO trials Publication: ESMO Annals of Oncology, Breast cancer, early stage, Volume 35, Supplement 2S346, September 2024 Authors: M. Rios Romero, O. Danielsson, T. Fornander, A. Nordenskjöld, G. Read More
Gene-expression assays to tailor adjuvant endocrine therapy
Clinical Cancer Research, Vol 30, Issue 14, July 15 2024 Author: Bottosso et al.
Read MoreUse of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades
PUBLICATION: JAMA Oncol. 2017;3(11):1503-1510. doi:10.1001/jamaoncol.2017.1261. AUTHORS: Laura J. Esserman, MD, MBA; Christina Yau, PhD; Carlie K. Thompson, MD; Laura J. van 't Veer, PhD; Alexander D. Borowsky, MD; Katherine A. Hoadley, PhD; Nicholas P. Tobin, PhD; Bo Nordenskjöld, MD, PhD; Tommy Fornander, MD, PhD; Olle Stål, PhD; Christopher C. Benz, Read More
Tamoxifen Therapy Benefit for Patients with 70-gene Signature High and Low Risk
PUBLICATION: Breast Cancer Res Treat (2017) 166: 593. https://doi.org/10.1007/s10549-017-4428-9. AUTHORS: Laura J. van ‘t Veer, Christina Yau, Nancy Y. Yu, Christopher C. Benz, Bo Nordenskjöld, Tommy Fornander, Olle Stål, Laura J. Esserman, Linda Sofie Lindström SUMMARY: 20yr BCSS and 10yr DMFS analysis of MammaPrint High Risk vs Low Risk patients Read More
